[go: up one dir, main page]

EP1957064A4 - Treatment of qt interval prolongation and diseases associated therewith - Google Patents

Treatment of qt interval prolongation and diseases associated therewith

Info

Publication number
EP1957064A4
EP1957064A4 EP06827886A EP06827886A EP1957064A4 EP 1957064 A4 EP1957064 A4 EP 1957064A4 EP 06827886 A EP06827886 A EP 06827886A EP 06827886 A EP06827886 A EP 06827886A EP 1957064 A4 EP1957064 A4 EP 1957064A4
Authority
EP
European Patent Office
Prior art keywords
treatment
associated therewith
diseases associated
interval prolongation
prolongation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06827886A
Other languages
German (de)
French (fr)
Other versions
EP1957064A2 (en
Inventor
Lin Zhao
Arthur Brown
Glenn Kirsch
Antonio Lacerda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tap Pharmaceuticals Inc
Original Assignee
Tap Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceuticals Inc filed Critical Tap Pharmaceuticals Inc
Publication of EP1957064A2 publication Critical patent/EP1957064A2/en
Publication of EP1957064A4 publication Critical patent/EP1957064A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EP06827886A 2005-11-21 2006-11-20 Treatment of qt interval prolongation and diseases associated therewith Withdrawn EP1957064A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73872405P 2005-11-21 2005-11-21
PCT/US2006/045042 WO2007062028A2 (en) 2005-11-21 2006-11-20 Treatment of qt interval prolongation and diseases associated therewith

Publications (2)

Publication Number Publication Date
EP1957064A2 EP1957064A2 (en) 2008-08-20
EP1957064A4 true EP1957064A4 (en) 2010-01-06

Family

ID=38067855

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06827886A Withdrawn EP1957064A4 (en) 2005-11-21 2006-11-20 Treatment of qt interval prolongation and diseases associated therewith

Country Status (4)

Country Link
EP (1) EP1957064A4 (en)
JP (1) JP2009516691A (en)
CA (1) CA2630639A1 (en)
WO (1) WO2007062028A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004018162D1 (en) 2003-09-04 2009-01-15 Neurosearch As hERG1-CHANNEL OPENER FOR THE TREATMENT OF HERZARRYTHMIES
EP2155643B1 (en) 2007-06-08 2016-08-10 MannKind Corporation Ire-1a inhibitors
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
IT1400309B1 (en) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND CALCIUM ANTAGONISTS AND THEIR USE.
IT1400609B1 (en) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND METFORMIN AND THEIR USE.
IT1400311B1 (en) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa ASSOCIATION OF INHIBITORS OF XANTHIN OXIDASE AND ANTAGONISTS OF THE Angiotensin II RECEPTOR AND THEIR USE.
IT1400310B1 (en) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND STATINES AND THEIR USE.
CN103298466B (en) 2010-09-10 2015-11-25 武田制药美国有限公司 The combinational therapeutic methods of theophylline and Febuxostat
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
CA2836904C (en) 2011-06-03 2019-09-24 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
TW201334779A (en) * 2012-01-27 2013-09-01 Teijin Pharma Ltd Therapeutic agent of diabetes mellitus
US9255093B2 (en) * 2014-04-17 2016-02-09 Novartis Ag Polycyclic HERG activators
EP3207931A3 (en) * 2014-06-03 2017-12-20 Signpath Pharma Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
CN106569163A (en) * 2015-10-08 2017-04-19 南京南瑞继保电气有限公司 Method for detecting trailing amount of transformer
CA3038813C (en) 2016-04-27 2021-08-24 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block
JP6954582B2 (en) * 2016-12-22 2021-10-27 国立大学法人滋賀医科大学 Pharmaceutical composition
CN110312528B (en) 2017-02-20 2022-02-18 国立大学法人京都大学 Pharmaceutical compositions and methods of treatment for genetic diseases resulting from splicing abnormalities
WO2018182346A1 (en) * 2017-03-30 2018-10-04 고려대학교 산학협력단 Composition for diagnosing or predicting drug-induced long qt syndrome, kit, and method for diagnosing or predicting drug-induced long qt syndrome using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023238A1 (en) * 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Erg channel openers for the treatment of hyperexcitability-related neuronal diseases
WO2005023237A1 (en) * 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Erg channel openers for the treatment of cardiac arrhythmias

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006509495A (en) * 2002-05-24 2006-03-23 ニューリオン ファーマシューティカルズ，インコーポレイティド Method for accurately measuring HERG interaction and modification of compound based on the interaction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023238A1 (en) * 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Erg channel openers for the treatment of hyperexcitability-related neuronal diseases
WO2005023237A1 (en) * 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Erg channel openers for the treatment of cardiac arrhythmias

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANG JIESHENG ET AL: "Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.", MOLECULAR PHARMACOLOGY MAR 2005, vol. 67, no. 3, March 2005 (2005-03-01), pages 827 - 836, XP002556830, ISSN: 0026-895X *
ZHOU JUN ET AL: "Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.", MOLECULAR PHARMACOLOGY SEP 2005, vol. 68, no. 3, September 2005 (2005-09-01), pages 876 - 884, XP002556829, ISSN: 0026-895X *

Also Published As

Publication number Publication date
EP1957064A2 (en) 2008-08-20
WO2007062028A3 (en) 2009-05-07
JP2009516691A (en) 2009-04-23
WO2007062028A8 (en) 2008-05-15
WO2007062028A2 (en) 2007-05-31
CA2630639A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
EP1957064A4 (en) Treatment of qt interval prolongation and diseases associated therewith
EP1968607A4 (en) Treatment of cancer and other diseases
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
IL189528A0 (en) Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
PL1951273T3 (en) Use of lactobacillus for treatment of autoimmune diseases
IL217839A0 (en) Pharmaceuticals compositions for the treatment of cancer and pther diseases or disorders
ZA200802935B (en) Use of lactobacillus for treatment of autoimmune diseases
HK1171972A1 (en) Methods and products for treatment of diseases
GB0603181D0 (en) Treatment of neurodegenerative and psychiatric diseases
EP2001488A4 (en) Prevention and treatment of cancer and other diseases
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1954800A4 (en) Composition and use of phyto-percolate for treatment of disease
EP1928247A4 (en) Composition and use of phyto-percolate for treatment of disease
EP1789047A4 (en) Treatment of diseases using nalmefene and its analgos
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
GB0604826D0 (en) The treatment of inflammatory disorders and pain
EP1773882A4 (en) Diagnosis and treatment of siglec-6 associated diseases
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB0526394D0 (en) Treatment of inflammatory diseases
IL185691A0 (en) Novel compounds derived from 5-thioxylose and therapeutic use thereof
ZA200710476B (en) Methods and compositions for the treatment of pain
GB0604822D0 (en) The treatment of inflammatory disorders and pain
EP1846013A4 (en) Treatment of skin diseases
GB0519274D0 (en) The treatment of neurodegenerative diseases
GB0724970D0 (en) Treatment and prevention of nuerodegenerative diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080612

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120445

Country of ref document: HK

R17D Deferred search report published (corrected)

Effective date: 20090507

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/44 20060101AFI20090623BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/06 20060101ALI20091124BHEP

Ipc: A61K 31/44 20060101ALI20091124BHEP

Ipc: A61K 31/426 20060101ALI20091124BHEP

Ipc: A61K 31/00 20060101AFI20091124BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100302

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1120445

Country of ref document: HK